The minimal inhibitory concentrations of cefmenoxime, cefotaxime, cefoxitin, ceftriaxone, chloramphenicol, clindamycin, and moxalactam were determined by agar dilution for 202 clinical isolates of anaerobic bacteria. Cefoxitin and moxalactam were the most active among the cephalosporin-like compounds.
The increased awareness of the roles played by anaerobic bacteria in infectious processes has brought with it a search for antimicrobial agents which provide effective therapy. Although penicillin still appears to be effective for the treatment of most pulmonary lesions associated with these agents, the selection of therapeutic agents for infections associated with abdominal foci remains limited. There has been a recent influx of new ,-lactam-related compounds which possess enhanced and broader antimicrobial activities than those of their predecessors (2) (3) (4) (5) (6) 10) . Data on the spectra of activity of cefmenoxime and ceftriaxone against anaerobic species are available for relatively small numbers of studies (1, 3, 6, 9) . In addition, several workers have examined the susceptibilities of some of these compounds to hydrolysis by the p-lactamase of Bacteroides fragilis (6, 8, 10) . There have been little data, however, on the susceptibilities of gram-positive anaerobes to these newer compounds (6, 9) . In addition, none of these studies has compared the activity of cefmenoxime with that of ceftriaxone.
The purpose of this study was to compare the antibacterial activities of two newer cephalosporin-like compounds, cefmenoxime and ceftriax- to 32, and >32 ,ug/ml (3) . MICs of >32 jig/ml probably represent resistance to these antibotics.
The MICs for the control strain B. thetaiotaomicron are shown in Table 1 . The MIC of all antibiotics tested was always <0.5 j,g/ml for the C. perfringens control strain. The results indicated great variation in the abilities of the new ,Blactams to inhibit the growth of anaerobes (Table 2). The MICs of cefmenoxime, cefotaxime, ceftriaxone, and moxalactam were all >32 ,ug/ml for some strains of B. fragilis, Bacteroides ovatus, Bacteroids vulgatus, B. thetaiotaomicron, and other Bacteroides spp. There were four strains of Bacteroides spp. with moxalactam MICs of 0.5 ,ug/ml, whereas only two strains had comparable cefoxitin MICs. Overall, cefoxitin appeared to be slightly more active than moxalactam against the Bacteroides group as a whole. species. Enzymatic studies of the P-lactamases of members of the B. fragilis group have demonstrated enzymatic activity against cefmenoxime and cefotaxime (7) but only minimal activity against moxalactam and cefoxitin (6, 7, 10) . Most Fusobacterium spp. were very susceptible, with four strains demonstrating ceftriaxone resistance, two of which were also resistant to cefmenoxime and cefotaxime. Activity against gram-positive isolates was variable. The few strains of Bifidobacterium spp. were susceptible to all compounds, as were most of the C. perfringens strains ( Table 2 ).
Three strains of Clostridium spp. were resistant to cefoxitin and cefotaxime, and only one was resistant to cefmenoxime and ceftriaxone.
Eubacterium spp. were least affected by cefmenoxime and cefotaxime. Four strains were resistant to ceftriaxone and three to moxalactam. Most strains of the anaerobic gram-positive cocci were highly susceptible to all of the compounds tested. Only two strains of each genus were resistant to moxalactam, and one strain of Peptococcus asaccharolyticus was highly resistant to both ceftriaxone and cefmenoxime.
As some of the ,B-lactamase studies have revealed, cefmenoxime, ceftriaxone, and cefotaxime are less resistant to enzymatic hydrolysis and less predictable in their activities against anaerobic bacteria than are moxalactam or cefoxitin (6, 8, 10) . Technically, moxalactam is a 1-oxa-13-lactam and cefoxitin is a cephamycin. The usefulness of these two compounds for therapeutic purposes in anaerobic infections remains to be seen; however, it is of interest that the 1-lactam ring of each is protected by an a-methoxy chemical group which may be related to their broader spectra of activity against anaerobic bacteria.
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